,i #aagth ,,congress #ast ,session ,h4 ,r4 #dhaa ,,in ,,the ,,house ,,of ,,representatives ,july #bi1 #bjba,mr4 ,doggett 7for himself1 ,mr4 ,beyer1 ,mr4 ,blumenauer1 ,mr4 ,bowman1 ,ms4 ,bush1 ,mr4 ,cartwright1 ,mr4 ,castro of ,texas1 ,mr4 ,cicilline1 ,mr4 ,cleaver1 ,mr4 ,cohen1 ,mr4 ,de,fazio1 ,ms4 ,de,lauro1 ,mrs4 ,dingell1 ,ms4 ,escobar1 ,mr4 ,espaillat1 ,mr4 ,garamendi1 ,mr4 ,garca of ,illinois1 ,mr4 ,green of ,texas1 ,mr4 ,grijalva1 ,ms4 ,jackson ,lee1 ,ms4 ,jayapal1 ,mr4 ,kahele1 ,ms4 ,kaptur1 ,mr4 ,khanna1 ,mr4 ,kim of ,new ,jersey1 ,mr4 ,krishnamoorthi1 ,mr4 ,langevin1 ,ms4 ,lee of ,california1 ,mr4 ,levin of ,michigan1 ,mr4 ,lowenthal1 ,mr4 ,mc,nerney1 ,mr4 ,mfume1 ,mr4 ,nadler1 ,mr4 ,neguse1 ,ms4 ,norton1 ,ms4 ,ocasio-,cortez1 ,ms4 ,omar1 ,mr4 ,perlmutter1 ,ms4 ,pingree1 ,mr4 ,pocan1 ,ms4 ,porter1 ,ms4 ,pressley1 ,mr4 ,raskin1 ,ms4 ,schakowsky1 ,mr4 ,sherman1 ,mr4 ,takano1 ,mr4 ,thompson of ,mississippi1 ,ms4 ,titus1 ,ms4 ,tlaib1 ,mr4 ,torres of ,new ,york1 ,mr4 ,vela1 ,mr4 ,yarmuth1 ,ms4 ,leger ,fernandez1 ,ms4 ,moore of ,wisconsin1 ,ms4 ,waters1 ,ms4 ,chu1 ,ms4 ,newman1 and ,ms4 ,velzquez7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committees on ,ways and ,means1 ,oversight and ,reform1 ,veterans' ,affairs1 and ,armed ,services1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to amend title ,,xviii of the ,social ,security ,act to require the ,secretary of ,health and ,human ,services to negotiate prices of drugs furnished under the ,medicare program1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,medicare ,negotiation and ,competitive ,licensing ,act of #bjba4 #b4 ,requiring the ,secretary of ,health and ,human ,services to negotiate prices of drugs furnished under the ,medicare program 7a7 ,part ,d ,section #ahfj;,d-#aa of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aaa7 is amended by striking subsection 7i7 and inserting the following new subsection3 7i7 ,negotiation of lower drug prices 7#a7 ,in general ,notwithstanding any other provision of law1 the ,secretary shall1 for plan years beginning on or after the date of the enactment of this subsection1 negotiate with pharmaceutical manufacturers the negotiated prices 7including discounts1 rebates1 and other price concessions7 that may be charged to ,,pdp sponsors and ,,ma organizations during a negotiated price period 7as specified by the ,secretary7 for specified covered part ,d drugs for such plan year for part ,d eligible individuals who are enrolled under a prescription drug plan or under an ,,ma-,,pd plan4 7#b7 ,negotiation considerations 7,a7 ,factors ,in negotiating such prices under paragraph 7#a71 the ,secretary shall take into account the following factors3 7i7 ,the comparative clinical effectiveness and cost effectiveness1 when available from an impartial source1 of such drug4 7ii7 ,the budgetary impact of providing coverage of such drug4 7iii7 ,the number of similarly effective drugs or alternative treatment regimens for each approved use of such drug4 7iv7 ,the associated financial burden on patients that utilize such drug4 7v7 ,the associated unmet patient need for such drug4 7vi7 ,the total revenues from global sales obtained by the manufacturer for such drug and the associated investment in research and development of such drug by the manufacturer4 7,b7 ,assessment of factors ,for purposes of assessing the factors described in subparagraph 7,a7 with respect to a covered part ,d drug1 the ,secretary shall1 as soon as practicable1 establish a value assessment process consisting of standardized measures for such factors4 ,with respect to a negotiation that occurs before the ,secretary establishes such a process1 the ,secretary may use such other assessments as the ,secretary determines appropriate 7such as assessments used with respect to ascertaining the value of drugs by the ,secretary of ,veterans ,affairs1 the ,patient-,centered ,outcomes ,research ,institute1 the ,institute for ,clinical and ,economic ,review1 and other countries74 7#c7 ,specified covered part ,d drugs ,in this subsection1 the term specified covered part ,d drug means1 with respect to a negotiated price period beginning during-- 7,a7 the first plan year beginning on or after the date of the enactment of this subsection1 a covered part ,d drug that is a sole source drug 7as defined in section #ahcc7t77#ad77;,f77i77-- 7i7 with respect to which gross revenues for the preceding plan year were #ajj1jjj1jjj or greater2 or 7ii7 that contains an active ingredient that was first approved by the ,administrator for ,food and ,drugs not later than #aj years prior to the beginning of such first plan year2 7,b7 the second plan year beginning on or after the date of the enactment of this subsection1 a covered part ,d drug that is a sole source drug 7as so defined7 or a biosimilar biological product2 7,c7 the third plan year beginning on or after the date of the enactment of this subsection1 a covered part ,d drug-- 7i7 that is described in subparagraph 7,b72 or 7ii7 with respect to which1 during the preceding plan year1 fewer than #c manufacturers 7other than the manufacturer of such drug7 marketed a generic version of such drug2 and 7,d7 the fourth plan year beginning on or after the date of the enactment of this subsection or a subsequent plan year1 a covered part ,d drug4 7#d7 ,negotiated price limitations and finalization ,the negotiated price of each specified covered part ,d drug for a negotiated price period-- 7,a7 may not be less than an amount necessary to allow such manufacturer to recoup such manufacturer's research and development costs associated with such drug2 7,b7 subject to subparagraph 7,a71 may not exceed #aaj percent of the median price of such drug for the preceding plan year in the #aj countries of the ,organisation for ,economic ,cooperation and ,development with the highest gross domestic product and with a per capita income that is not less than half the per capita income of the ,united ,states for such preceding plan year2 and 7,c7 shall be finalized not later than #cj days before a ,,pdp sponsor is required to submit information described in subsection 7b77#b7 for the first plan year in such negotiated price period4 7#e7 ,competitive licensing authority 7,a7 ,in general ,notwithstanding any exclusivity under clause 7iii7 or 7iv7 of section #eje7;j77#e77;,f7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 clause 7iii7 or 7iv7 of section #eje7;c77#c77;,e7 of such ,act1 section #cea7k77#g77;,a7 of the ,public ,health ,service ,act1 or section #ebg7;a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 or by an extension of such exclusivity under section #eje;,a of such ,act or section #eje;,e of such ,act1 and any other provision of law that provides for market exclusivity 7or extension of market exclusivity7 with respect to a drug1 in the case that the ,secretary is unable to successfully negotiate an appropriate price for a specified covered part ,d drug for a negotiated price period1 the ,secretary shall authorize the use of any patent1 clinical trial data1 or other exclusivity granted by the ,federal government with respect to such drug as the ,secretary determines appropriate for purposes of manufacturing such drug for sale under a ,federal health care program1 the insurance program under chapter #hi of title #e1 ,united ,states ,code1 or a group health plan or health insurance coverage offered by a health insurance issuer4 ,any entity making use of a competitive license to use patent1 clinical trial data1 or other exclusivity under this section shall provide to the manufacturer holding such exclusivity reasonable compensation1 as determined by the ,secretary based on the following factors3 7i7 ,the risk-adjusted value of any ,federal government subsidies and investments in research and development used to support the development of such drug4 7ii7 ,the risk-adjusted value of any investment made by such manufacturer in the research and development of such drug4 7iii7 ,the impact of the price1 including license compensation payments1 on meeting the medical need of all patients4 7iv7 ,the relationship between the price of such drug1 including compensation payments1 and the health benefits of such drug4 7v7 ,other relevant factors determined appropriate by the ,secretary to provide reasonable compensation4 7,b7 ,reasonable compensation 7i7 ,limitations ,reasonable compensation described in subparagraph 7,a7 with respect to a specified covered outpatient drug and a plan year may not be made in an amount-- 7,i7 less than an amount necessary to allow such manufacturer to recoup such manufacturer's research and development costs associated with such drug2 and 7,,ii7 subject to subclause 7,i71 greater than #ab percent of the negotiated price set by the ,secretary for such drug and such plan year4 7ii7 ,recovery ,the manufacturer described in subparagraph 7,a7 may seek recovery against the ,united ,states in the ,united ,states ,court of ,federal ,claims4 7,c7 ,interim period ,until #a year after a drug described in subparagraph 7,a7 is approved under section #eje7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act or section #cea7k7 of the ,public ,health ,service ,act and is provided under license issued by the ,secretary under such subparagraph1 ,,pdp plans and ,,ma-,,pd plans shall not pay more for such drug than #aaj percent of the median of the prices available1 during the most recent #ab-month period for which data is available prior to the beginning of such negotiated price period1 from the manufacturer to any wholesaler1 retailer1 provider1 health maintenance organization1 nonprofit entity1 or governmental entity in the ten ,organisation for ,economic ,cooperation and ,development countries that have the largest gross domestic product with a per capita income that is not less than half the per capita income of the ,united ,states4 7,d7 ,authorization for secretary to procure drugs directly 7i7 ,in general ,the ,secretary may procure a drug manufactured pursuant to a competitive license under subparagraph 7,a7 for purposes of this part or pursuant to a ,federal program license under subparagraph 7,c77ii7 for purposes of a ,federal program directly from the entity manufacturing the drug pursuant to such a license4 7ii7 ,clarification regarding application of buy american act ,in the case where the ,secretary procures a drug under this subparagraph1 the provisions of chapter #hc of title #da1 ,united ,states ,code 7commonly referred to as the ,buy ,american ,act7 shall apply4 7,e7 ,priority for u4s4 manufacturers in authorizing competitive licenses ,in authorizing a competitive license under this paragraph1 the ,secretary-- 7i7 shall give preference to entities that the ,secretary determines have the highest safety and security standards2 and 7ii7 may give priority to entities that will manufacture such drug in the ,united ,states4 7#f7 ,,fda review of licensed drug applications ,the ,secretary shall prioritize review of applications under section #eje7;j7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act for drugs licensed under paragraph 7#c77;,a74 7#g7 ,prohibition of anticompetitive behavior ,no drug manufacturer may engage in anticompetitive behavior with another manufacturer that may interfere with the issuance and implementation of a competitive license or run contrary to public policy4 7#h7 ,required reporting ,the ,secretary may require pharmaceutical manufacturers or any other entity to disclose to the ,secretary such information that the ,secretary determines necessary for purposes of carrying out this subsection4 7#i7 ,clarification ,nothing in this subsection shall be construed as preventing the sponsor of a prescription drug plan or an organization offering an ,,ma-,,pd plan from obtaining a discount or reduction of the price for a covered part ,d drug below the price negotiated by the ,secretary4 7#aj7 ,publication of negotiated prices and contract terms ,the ,secretary shall make available on a public website the price negotiated under this subsection1 and any contract terms associated with such price1 with respect to each specified covered part ,d drug4 4 7b7 ,part ,b 7#a7 ,in general ,section #ahdb7o7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acieu7o77 is amended by adding at the end the following new paragraph3 7#h7 7,a7 ,notwithstanding any preceding provision of this subsection1 in the case of a drug or biological described in paragraph 7#a7 furnished during a negotiated price period beginning on or after ,january #a of the first year beginning on or after the date of the enactment of this paragraph1 the amount payable under this part for such drug or biological shall be equal to the negotiated price for such drug or biological and period1 as established pursuant to subparagraph 7,b74 7,b7 ,the provisions of section #ahfj;,d-#aa7;i7 shall be applied to the negotiation of a negotiated price for a drug or biological described in subparagraph 7,a7 and a negotiated price period in a similar manner 7as determined by the ,secretary7 as such provisions apply with respect to the negotiation of a negotiated price for a specified part ,d drug for a negotiated price period under such section4 4 7#b7 ,application to ,,ma ,section #aheb of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#bb7 is amended by adding at the end the following new subsection3 7o7 ,limitation on reimbursement for certain drugs ,in the case of a drug or biological furnished during a negotiated price period 7as defined for purposes of section #ahdb7o77#h77 for which payment may be made under such section1 the total reimbursement for such drug or biological made by an ,medicare ,advantage plan may not exceed the negotiated price for such drug or biological and period established pursuant to such section4 4 #c4 ,identification of prescription drug price spikes 7a7 ,definitions ,in this section3 7#a7 ,applicable entity ,the term applicable entity means the holder of an application approved under subsection 7c7 or 7j7 of section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 or of a license issued under subsection 7a7 or 7k7 of section #cea of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7 for a drug described in paragraph 7#e77;,a74 7#b7 ,average manufacturer price ,the term average manufacturer price-- 7,a7 has the same meaning given such term under section #aibg7k77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7k77#a772 or 7,b7 with respect to a drug for which there is no average manufacturer price as so defined1 such term shall mean the wholesale acquisition cost of the drug4 7#c7 ,commerce ,the term commerce has the meaning given such term in section #d of the ,federal ,trade ,commission ,act 7#ae ,u4,s4,c4 #dd74 7#d7 ,inspector ,general ,the term ,inspector ,general means the ,inspector ,general of the ,department of ,health and ,human ,services4 7#e7 ,prescription drug 7,a7 ,in general ,the term prescription drug means any drug 7as defined in section #bja7;g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cba7;g7771 including a combination product whose primary mode of action is determined under section #ejc7;g7 of such ,act 7#ba ,u4,s4,c4 #cec7;g77 to be that of a drug1 and that-- 7i7 is subject to section #ejc7;b77#a7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cec7;b77#a772 and 7ii7 is covered by a ,federal health care program 7as defined in section #aabh;,b7f7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;a-#g;b7f7774 7,b7 ,treatment of reformulated drugs ,for purposes of this section1 a prescription drug with respect to which the ,secretary of ,health and ,human ,services has approved any minor reformulation that does not produce a meaningful therapeutic benefit1 the drug that was approved prior to any such reformulation and the drug with any such reformulation shall be considered one prescription drug4 7#f7 ,price spike 7,a7 ,in general ,the term price spike means an increase in the average manufacturer price in commerce of a prescription drug for which the price spike percentage is equal to or greater than applicable price increase allowance4 7,b7 ,price spike percentage ,the price spike percentage is the percentage 7if any7 by which-- 7i7 the average manufacturer price of a prescription drug in commerce for the calendar year2 exceeds 7ii7 the average manufacturer price of such prescription drug in commerce for the calendar year preceding such year4 7,c7 ,applicable price increase allowance ,the applicable price increase allowance for any calendar year is the percentage 7rounded to the nearest one-tenth of #a percent7 by which the ,c-,,cpi-,u 7as defined in section #a7;f77#f7 of the ,internal ,revenue ,code of #aihf7 for that year exceeds the ,c-,,cpi-,u for the preceding calendar year4 7#g7 ,price spike revenue 7,a7 ,in general ,the price spike revenue for any calendar year is an amount equal to-- 7i7 the gross price spike revenue1 minus 7ii7 the adjustment amount4 7,b7 ,gross price spike revenue ,the gross price spike revenue for any calendar year is an amount equal to the product of-- 7i7 an amount equal to the difference between clause 7i7 of paragraph 7#f77;,b7 and clause 7ii7 of such paragraph2 and 7ii7 the total number of units of the prescription drug which were sold in commerce in such calendar year4 7,c7 ,adjustment amount ,the adjustment amount is the amount1 if any1 of the gross price spike revenue which the ,inspector ,general has determined is due solely to an increase in the cost of the inputs necessary to manufacture the prescription drug subject to the price spike4 7b7 ,submission by pharmaceutical companies of information to ,inspector ,general 7#a7 ,in general ,for each prescription drug1 the applicable entity shall submit to the ,inspector ,general a quarterly report that includes the following3 7,a7 ,for each prescription drug of the applicable entity-- 7i7 the total number of units of the prescription drug which were sold in commerce in the preceding calendar quarter2 7ii7 the average and median price per unit of such prescription drug in commerce in the preceding calendar quarter1 disaggregated by month2 and 7iii7 the gross revenues from sales of such prescription drug in commerce in the preceding calendar quarter4 7,b7 ,such information related to increased input costs or public health considerations as the applicable entity may wish the ,inspector ,general to consider in making a determination under clause 7ii7 of subsection 7c77#b77;,b7 or an assessment in clause 7iii7 of such subsection for the preceding calendar quarter4 7,c7 ,such information related to any anticipated increased input costs for the subsequent calendar quarter as the applicable entity may wish the ,inspector ,general to consider in making a determination under clause 7ii7 of subsection 7c77#b77;,b7 or an assessment in clause 7iii7 of such subsection for such calendar quarter4 7#b7 ,penalty for failure to submit 7,a7 ,in general ,an applicable entity described in paragraph 7#a7 that fails to submit information to the ,inspector ,general regarding a prescription drug1 as required by such paragraph1 before the date specified in paragraph 7#c7 shall be liable for a civil penalty1 as determined under subparagraph 7,b74 7,b7 ,amount of penalty ,the amount of the civil penalty shall be equal to the product of-- 7i7 an amount1 as determined appropriate by the ,inspector ,general1 which is-- 7,i7 not less than #j4e percent of the gross revenues from sales of the prescription drug described in subparagraph 7,a7 for the preceding calendar year1 and 7,,ii7 not greater than #a percent of the gross revenues from sales of such prescription drug for the preceding calendar year1 and 7ii7 the number of days in the period between-- 7,i7 the applicable date specified in paragraph 7#c71 and 7,,ii7 the date on which the ,inspector ,general receives the information described in paragraph 7#a7 from the applicable entity4 7#c7 ,submission deadline ,an applicable entity shall submit each quarterly report described in paragraph 7#a7 not later than ,january #ag1 ,april #ah1 ,june #ae1 and ,september #ae of each calendar year4 7c7 ,assessment by ,inspector ,general 7#a7 ,in general ,not later than the last day in ,february of each year1 the ,inspector ,general1 in consultation with other relevant ,federal agencies 7including the ,federal ,trade ,commission71 shall-- 7,a7 complete an assessment of the information the ,inspector ,general received pursuant to subsection 7b77#a7 with respect to sales of prescription drugs in the preceding calendar year2 and 7,b7 in the case of any prescription drug which satisfies the conditions described in paragraph 7#a7 or 7#b7 of subsection 7d71 submit a recommendation to the ,secretary of ,health and ,human ,services that such drug be exempted from application of the tax imposed under section #daib of the ,internal ,revenue ,code of #aihf 7as added by section #c of this ,act7 for such year4 7#b7 ,elements ,the assessment required by paragraph 7#a77;,a7 shall include the following3 7,a7 ,identification of each price spike relating to a prescription drug in the preceding calendar year4 7,b7 ,for each price spike identified under subparagraph 7,a7-- 7i7 a determination of the price spike revenue2 7ii7 a determination regarding the accuracy of the information submitted by the applicable entity regarding increased input costs2 and 7iii7 an assessment of the rationale of the applicable entity for the price spike4 7d7 ,exemption of certain drugs 7#a7 ,in general ,the ,secretary of ,health and ,human ,services1 upon recommendation of the ,inspector ,general pursuant to subsection 7c77#a77;,b71 may exempt any prescription drug which has been subject to a price spike during the preceding calendar year from application of the tax imposed under section #daib of the ,internal ,revenue ,code of #aihf for such year1 if the ,secretary determines that-- 7,a7 based on information submitted pursuant to subsection 7b77#a77;,b71 a for-cause price increase exemption should apply2 or 7,b7 7i7 the prescription drug which has been subject to a price spike has an average manufacturer price of not greater than #aj for a #cj day supply2 and 7ii7 such drug is marketed by not less than #c other holders of applications approved under subsection 7c7 or 7j7 of section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee71 where such applications approved under such subsection 7j7 use as a reference drug the drug so approved under such subsection 7c74 7#b7 ,clarification ,in considering1 under paragraph 7#a77;,a71 information submitted pursuant to subsection 7b77#a77;,b71 the ,secretary-- 7,a7 has the discretion to determine that such information does not warrant a for-cause price increase exemption2 and 7,b7 shall exclude from such consideration any information submitted by the applicable entity threatening to curtail or limit production of the prescription drug if the ,secretary does not grant an exemption from the application of the tax under section #daib of the ,internal ,revenue ,code of #aihf4 7e7 ,inspector ,general report to ,internal ,revenue ,service 7#a7 ,in general ,subject to paragraph 7#c71 not later than the last day in ,february of each year1 the ,inspector ,general shall transmit to the ,internal ,revenue ,service a report on the findings of the ,inspector ,general with respect to the information the ,inspector ,general received under subsection 7b77#a7 with respect to the preceding calendar year and the assessment carried out by the ,inspector ,general under subsection 7c77#a77;,a7 with respect to such information4 7#b7 ,contents ,the report transmitted under paragraph 7#a7 shall include the following3 7,a7 ,the information received under subsection 7b77#a7 with respect to the preceding calendar year4 7,b7 ,the price spikes identified under subparagraph 7,a7 of subsection 7c77#b74 7,c7 ,the price spike revenue determinations made under subparagraph 7,b77i7 of such subsection4 7,d7 ,the determinations and assessments made under clauses 7ii7 and 7iii7 of subparagraph 7,b7 of such subsection4 7#c7 ,notice and opportunity for hearing 7,a7 ,in general ,no report shall be transmitted to the ,internal ,revenue ,service under paragraph 7#a7 in regards to a prescription drug unless the ,inspector ,general has provided the applicable entity with-- 7i7 the assessment of such drug under subsection 7c77#a77;,a72 and 7ii7 notice of their right to a hearing in regards to such assessment4 7,b7 ,notice ,the notice required under subparagraph 7,a7 shall be provided to the applicable entity not later than #cj days after completion of the assessment under subsection 7c77#a77;,a74 7,c7 ,request for hearing ,subject to subparagraph 7,e71 an applicable entity may request a hearing before the ,secretary of ,health and ,human ,services not later than #cj days after the date on which the notice under subparagraph 7,b7 is received4 7,d7 ,completion of hearing ,in the case of an applicable entity which requests a hearing pursuant to subparagraph 7,c71 the ,secretary of ,health and ,human ,services shall1 not later than #ab months after the date on which the assessment under subsection 7c77#a77;,a7 was completed by the ,inspector ,general-- 7i7 make a final determination in regards to the accuracy of such assessment2 and 7ii7 provide the report described in paragraph 7#b7 to the ,internal ,revenue ,service4 7,e7 ,limitation ,an applicable entity may request a hearing under subparagraph 7,c7 with respect to a particular prescription drug only once within a #e-year period4 7#d7 ,publication 7,a7 ,in general ,not later than the last day in ,february of each year1 subject to subparagraph 7,b71 the ,inspector ,general shall make the report transmitted under paragraph 7#a7 available to the public1 including on the ,internet website of the ,inspector ,general1 subject to subparagraph 7,b74 7,b7 ,proprietary information ,the ,inspector ,general shall ensure that any information made public in accordance with subparagraph 7,a7 excludes trade secrets and confidential commercial information4 7f7 ,notification ,the ,secretary of the ,treasury1 in conjunction with the ,inspector ,general1 shall notify1 at such time and in such manner as the ,secretary of the ,treasury shall provide1 each applicable entity in regard to any prescription drug which has been determined to have been subject to a price spike during the preceding calendar year and the amount of the tax imposed on such applicable entity pursuant to section #daib of the ,internal ,revenue ,code of #aihf4 #d4 ,excise tax on prescription drugs subject to price spikes 7a7 ,in general ,subchapter ,e of chapter #cb of the ,internal ,revenue ,code of #aihf is amended by adding at the end the following new section3 #daib4 ,prescription drugs subject to price spikes 7a7 ,imposition of tax 7#a7 ,in general ,subject to paragraph 7#c71 for each taxable prescription drug sold by an applicable entity during the calendar year1 there is hereby imposed on such entity a tax equal to the greater of-- 7,a7 the annual price spike tax for such prescription drug1 or 7,b7 subject to paragraph 7#b71 the cumulative price spike tax for such prescription drug4 7#b7 ,limitation ,in the case of a taxable prescription drug for which the applicable period 7as determined under subsection 7c77#b77;,e77i77 is less than #b calendar years1 the cumulative price spike tax shall not apply4 7#c7 ,exemption ,for any calendar year in which the ,secretary of ,health and ,human ,services has provided an exemption for a taxable prescription drug pursuant to section #c7;d7 of the ,medicare ,negotiation and ,competitive ,licensing ,act of #bjba1 the amount of the tax determined under paragraph 7#a7 for such drug or device for such calendar year shall be reduced to zero4 7b7 ,annual price spike tax 7#a7 ,in general ,the amount of the annual price spike tax shall be equal to the applicable percentage of the price spike revenue received by the applicable entity on the sale of the taxable prescription drug during the calendar year4 7#b7 ,applicable percentage ,for purposes of paragraph 7#a71 the applicable percentage shall be equal to-- 7,a7 in the case of a taxable prescription drug which has been subject to a price spike percentage greater than the applicable price increase allowance 7as defined in section #c7;a77#f77;,c7 of the ,medicare ,negotiation and ,competitive ,licensing ,act of #bjba7 but less than #ae percent1 #ej percent1 7,b7 in the case of a taxable prescription drug which has been subject to a price spike percentage equal to or greater than #ae percent but less than #bj percent1 #ge percent1 and 7,c7 in the case of a taxable prescription drug which has been subject to a price spike percentage equal to or greater than #bj percent1 #ajj percent4 7c7 ,cumulative price spike tax 7#a7 ,in general ,the amount of the cumulative price spike tax shall be equal to the applicable percentage of the cumulative price spike revenue received by the applicable entity on the sale of the taxable prescription drug during the calendar year4 7#b7 ,applicable percentage 7,a7 ,in general ,for purposes of paragraph 7#a71 the applicable percentage shall be equal to-- 7i7 in the case of a taxable prescription drug which has been subject to a cumulative price spike percentage greater than the cumulative price increase allowance but less than the first multi-year percentage1 #ej percent1 7ii7 in the case of a taxable prescription drug which has been subject to a cumulative price spike percentage equal to or greater than the first multi-year percentage but less than the second multi-year percentage1 #ge percent1 and 7iii7 in the case of a taxable prescription drug which has been subject to a cumulative price spike percentage equal to or greater than the second multi-year percentage1 #ajj percent4 7,b7 ,cumulative price spike percentage ,the cumulative price spike percentage is the percentage 7if any7 by which-- 7i7 the average manufacturer price of the taxable prescription drug in commerce for the preceding calendar year1 exceeds 7ii7 the average manufacturer price of such prescription drug in commerce for the base year4 7,c7 ,cumulative price increase allowance ,for purposes of clause 7i7 of subparagraph 7,a71 the cumulative price increase allowance for any calendar year is the percentage 7rounded to the nearest one-tenth of #a percent7 by which the ,c-,,cpi-,u 7as defined in section #a7;f77#f77 for that year exceeds the ,c-,,cpi-,u for the base year4 7,d7 ,multi-year percentages ,for purposes of subparagraph 7,a71 the first multi-year percentage and second multi-year percentage shall be determined in accordance with the following table3 ,number of years in applicable period,first multi-year percentage,second multi-year percentage#b years#ag4ebb4ec years#bjbed years#bb4ebg4ee years#becj4 7,e7 ,applicable period and base year 7i7 ,applicable period ,the applicable period shall be the lesser of-- 7,i7 the #e preceding calendar years1 7,,ii7 all calendar years beginning after the date of enactment of this section1 or 7,,iii7 all calendar years in which the taxable prescription drug was sold in commerce4 7ii7 ,base year ,the base year shall be the calendar year immediately preceding the applicable period4 7#c7 ,cumulative price spike revenue ,for purposes of paragraph 7#a71 the cumulative price spike revenue for any taxable prescription drug shall be an amount equal to-- 7,a7 an amount equal to the product of-- 7i7 an amount 7not less than zero7 equal to-- 7,i7 the average manufacturer price of such prescription drug in commerce for the preceding calendar year1 minus 7,,ii7 the average manufacturer price of such prescription drug in commerce for the base year1 and 7ii7 the total number of units of such prescription drug which were sold in commerce in the preceding calendar year1 minus 7,b7 an amount equal to the sum of the adjustment amounts1 if any1 determined under section #c7;a77#g77;,c7 of the ,medicare ,negotiation and ,competitive ,licensing ,act of #bjba for each calendar year during the applicable period4 7d7 ,definitions ,for purposes of this section-- 7#a7 ,taxable prescription drug ,the term taxable prescription drug means a prescription drug which has been identified by the ,inspector ,general of the ,department of ,health and ,human ,services as being subject to a price spike4 7#b7 ,other terms ,the terms applicable entity1 average manufacturer price1 price spike1 price spike percentage1 and price spike revenue have the same meaning given such terms under section #c7;a7 of the ,medicare ,negotiation and ,competitive ,licensing ,act of #bjba4 4 7b7 ,clerical amendments 7#a7 ,the heading of subchapter ,e of chapter #cb of the ,internal ,revenue ,code of #aihf is amended by striking ,medical devices and inserting ,certain medical devices and prescription drugs4 7#b7 ,the table of subchapters for chapter #cb of such ,code is amended by striking the item relating to subchapter ,e and inserting the following new item3 ,subchapter ,e4 ,certain medical devices and prescription drugs 4 7#c7 ,the table of sections for subchapter ,e of chapter #cb of such ,code is amended by adding at the end the following new item3 ,sec4 #daib4 ,prescription drugs subject to price spikes4 4 7c7 ,effective date ,the amendments made by this section shall apply to sales after the date of the enactment of this ,act4 #e4 ,application of ,medicare prices to other insurers and the uninsured 7a7 ,federal health care programs ,part ,a of title ,,xi of the ,social ,security ,act 7#db ,u4,s4,c4 #acja et seq47 is amended by adding at the end the following new section3 #aaej;,c4 ,application of ,medicare negotiated prices 7a7 ,in general ,notwithstanding any other provision of law1 the price recognized under a ,federal health care program 7as defined in section #aabh;,b7 or the insurance program established under chapter #hi of title #e1 ,united ,states ,code1 for a specified covered part ,d drug 7as defined in section #ahfj;,d-#aa7;i771 or a drug or biological for which payment may be made under section #ahdb7o71 with respect to a year for which coverage is provided under such ,federal health care program or such insurance program may not exceed the price for such drug established under such section #ahfj;,d-#aa7;i7 or #ahdb7o71 as applicable4 7b7 ,application of other provisions ,the provisions of section #ahfj;,d-#aa7;i7 shall apply with respect to a ,federal health care program and the insurance program established under chapter #hi of title #e1 ,united ,states ,code1 in the same manner as such provisions apply with respect to a prescription drug plan or an ,,ma-,,pd plan under part ,d or ,c1 respectively1 of title ,,xviii4 4 7b7 ,private insurer ,subpart ,,ii of part ,a of title ,,xxvii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#aa et seq47 is amended by adding at the end the following new section3 #bgcj4 ,application of ,medicare negotiated prices 7a7 ,in general ,notwithstanding any other provision of law1 the price recognized under a group health plan1 or under individual or group health insurance coverage offered by a health insurance issuer1 for a specified covered part ,d drug 7as defined in section #ahfj;,d-#aa7;i771 or a drug or biological for which payment may be made under section #ahdb7o71 with respect to a year for which coverage is provided under such plan or such coverage may not exceed the price for such drug established under such section #ahfj;,d-#aa7;i7 or #ahdb7o71 as applicable4 7b7 ,application of other provisions ,the provisions of section #ahfj;,d-#aa7;i7 shall apply with respect to a group health plan1 or individual or group health insurance coverage offered by a health insurance issuer1 in the same manner as such provisions apply with respect to a prescription drug plan or an ,,ma-,,pd plan under part ,d or ,c1 respectively1 of title ,,xviii4 4 7c7 ,uninsured 7#a7 ,in general ,notwithstanding any other provision of law1 the amount that a pharmacy furnishing a drug to a specified individual 7as defined in paragraph 7#b77 may require as payment for such drug from such individual shall not exceed the price for such drug established under section #ahfj;,d-#aa7;i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aaa7;i77 7or1 if applicable1 under section #ahdb7o77#h7 of such ,act74 7#b7 ,definition ,for purposes of paragraph 7#a71 the term specified individual means1 with respect to a drug1 an individual who is not covered1 or who has no coverage with respect to such drug1 under a group health plan or group or individual health insurance coverage 7as such terms are defined in section #bgia of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ia77 or under a ,federal health care program 7as defined in section #aabh;,b of the ,social ,security ,act1 but including the insurance program established under chapter #hi of title #e1 ,united ,states ,code74 7#c7 ,enforcement ,the ,secretary of ,health and ,human ,services may impose a civil monetary penalty of not more than #aj1jjj per day on a pharmacy for a violation of paragraph 7#a74 #f4 ,manufacturer provision of information 7a7 ,in general ,in the case of a manufacturer of a drug or biological subject to a competitive licensing agreement under section #ahfj;,d-#aa7;i77#e7 of the ,social ,security ,act1 as added by this ,act1 such manufacturer shall1 upon request from an entity electing to manufacture such drug or biological1 provide to such entity materials1 data1 and information relating to the manufacture or supply of such drug or biological1 including-- 7#a7 cellular clones and hybridoma stocks2 7#b7 plasmids1 plasmid maps1 and sequences of antibody complementarity determining regions2 7#c7 physicochemical and biophysical characterization2 7#d7 growth conditions and protocols2 7#e7 attenuation or inactivation protocols2 7#f7 extraction and purification protocols2 7#g7 synthetic work-up and schemes2 7#h7 sufficient quantities of the drug or biological for testing2 7#i7 the protocols and methods used for testing the drug or biological2 and 7#aj7 the expected outcomes from those protocols4 7b7 ,enforcement ,the ,secretary of ,health and ,human ,services may impose a civil monetary penalty on a manufacturer of not more than #aj1jjj per day for a violation of subsection 7a74 #g4 ,applicability of negotiated price to prescription drugs furnished by the ,department of ,defense and the ,department of ,veterans ,affairs 7a7 ,in general ,section #habf7;a7 of title #ch1 ,united ,states ,code1 is amended-- 7#a7 in paragraph 7#b71 by inserting 1 but may not exceed the amount of the price negotiated by the ,secretary of ,health and ,human ,services under section #ahfj;,d-#aa7;i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aaa7;i77 7as amended by the ,medicare ,negotiation and ,competitive ,licensing ,act of #bjai7 for a specified covered part ,d drug 7as defined in such section7 7or1 if applicable1 may not exceed the amount of the price negotiated by the ,secretary of ,health and ,human ,services under section #ahdb7o77#h7 of such ,act for a drug or biological payable under such section7 that is a covered drug of a manufacturer after best interests of the ,department or such ,federal agencies2 and 7#b7 in paragraph 7#c71 by inserting or1 for a covered drug of a manufacturer that is a specified covered part ,d drug 7as defined in section #ahfj;,d-#aa7;i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aaa7;i77 7as amended by the ,medicare ,negotiation and ,competitive ,licensing ,act of #bjai77 or a drug or biological for which payment may be made under section #ahdb7o77#h7 of such ,act1 the price negotiated by the ,secretary of ,health and ,human ,services under such section #ahjf;,d-#aa7;i7 or #ahdb7o77#h7 7as applicable7 for the specified covered part ,d drug or the drug or biological after the price charged under the ,federal ,supply ,schedule at the time the drug is procured4 7b7 ,department of ,defense elements for purposes of pricing standards ,section #ajgd;g7f7 of title #aj1 ,united ,states ,code1 is amended-- 7#a7 in the header1 by inserting and national mail-,order pharmacy program after pharmacy program2 7#b7 by striking the ,,tricare retail pharmacy program shall be treated as an element of the ,department of ,defense and inserting the ,,tricare retail pharmacy program and the national mail-order pharmacy program shall be treated as elements of the ,department of ,defense2 and 7#c7 by striking provided by pharmacies under the program and inserting provided under such programs4 #h4 ,specified covered part ,d drugs excise tax 7a7 ,in general ,subchapter ,e of chapter #cb of the ,internal ,revenue ,code of #aihf is amended by adding at the end the following new section3 #daic4 ,specified covered part ,d drugs 7a7 ,in general ,there is hereby imposed on the sale by the manufacturer1 producer1 or importer of any specified covered part ,d drug for a price in excess of the negotiated price in violation of section #ahfj;,d-#aa7;i77#e77;,c7 of the ,social ,security ,act during any period described in such section a tax equal to #ajj percent of the price for which so sold4 7b7 ,definitions ,the terms specified covered part ,d drug and negotiated price have the meaning such terms have under section #ahfj;,d-#aa of the ,social ,security ,act4 4 7b7 ,clerical amendments 7#a7 ,the heading of subchapter ,e of chapter #cb of the ,internal ,revenue ,code of #aihf is amended by striking ,medical devices and inserting ,other medical products4 7#b7 ,the table of subchapters for chapter #cb of such ,code is amended by striking the item relating to subchapter ,e and inserting the following new item3 ,subchapter ,e4 ,other medical products 4 7#c7 ,the table of sections for subchapter ,e of chapter #cb of such ,code is amended by adding at the end the following new item3 ,sec4 #daic4 ,specified covered part ,d drugs4 4 7c7 ,effective date ,the amendments made by this section shall apply to sales on or after the date that is #a year after the date of the enactment of this ,act4 #i4 ,drug manufacturer reporting ,part ,p of title ,,iii of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bhj;g et seq47 is amended by adding at the end the following3 #cii,v-#g4 ,drug manufacturer reporting 7a7 ,mandatory reporting ,a drug manufacturer shall submit to the ,secretary and to ,congress an annual report specifying with respect to the previous calendar year 7except as provided in subsection 7d77#b77-- 7#a7 the total expenditures of the manufacturer on-- 7,a7 domestic and foreign drug research and development1 including an itemized description of-- 7i7 basic and preclinical research2 7ii7 clinical research1 reported separately for each clinical trial2 7iii7 development of alternative dosage forms and strengths for the drug molecule or combinations1 including the molecule2 7iv7 other drug development activities1 such as nonclinical laboratory studies and record and report maintenance2 7v7 pursuing new or expanded indications for such drug through supplemental applications under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act2 7vi7 carrying out postmarket requirements related to such drug1 including under section #eje7o77#c7 of such ,act2 7vii7 carrying out risk evaluation and mitigation strategies in accordance with section #eje-a of such ,act2 and 7viii7 marketing research2 7,b7 the acquisition of drug components and packaging1 in total and per unit sold1 broken out by source and cost and identifying specific costs that reflect internal transfers within the manufacturer's company2 7,c7 other acquisitions relating to drugs1 including for the purchase of patents and licensing or the acquisition of any corporate entity owning any rights to a drug during or after development of the drug2 and 7,d7 marketing1 advertising1 and educating for the promotion of a drug1 including a breakdown of amounts aimed at consumers1 prescribers1 managed care organizations1 and others1 irrespective of whether a particular drug is mentioned in the marketing1 advertising1 or educating2 7#b7 the gross revenue1 net revenue1 gross profit1 and net profit of the manufacturer with respect to drugs2 7#c7 the total number of units of each type of drug that were sold in interstate commerce2 7#d7 pricing information with respect to the sale of drugs1 including-- 7,a7 wholesale acquisition cost2 7,b7 net average price realized by prescription drug benefit managers for drugs provided to individuals in the ,united ,states1 after accounting for any rebates or other payments from the manufacturer to the pharmacy benefit manager and from the pharmacy benefit manager to the manufacturer2 and 7,c7 the net price of each drug1 after accounting for discounts1 rebates1 or other financial considerations1 charged to purchasers in each applicable country of the ,organisation for ,economic ,co-operation and ,development2 7#e7 any ,federal benefits received by the manufacturer with respect to a drug1 including the amounts and periods of impact for each such benefit1 including tax credits2 ,federal grants1 including from the ,national ,institutes of ,health1 the ,department of ,defense1 the ,department of ,energy1 the ,centers for ,disease ,control and ,prevention1 or other ,federal departments or agencies2 patent applications that benefitted from such grants2 patent extensions2 exclusivity periods2 and waivers of fees2 7#f7 the percentage of research and development expenditures described in clauses 7i7 through 7v7 of paragraph 7#a77;,a7 that were derived from ,federal funds2 7#g7 executive compensation for the chief executive officer1 chief financial officer1 and the #c other most highly compensated executive officers1 including bonuses1 paid by such manufacturer1 and stock options affiliated with the manufacturer that were offered to or accrued by such officers2 and 7#h7 any other information as the ,secretary may require4 7b7 ,voluntary supplemental reporting ,a drug manufacturer may supplement a report under subsection 7a7 with any additional information the manufacturer chooses to provide related to drug pricing decisions1 such as-- 7#a7 total expenditures on drug research1 drug development1 and clinical trials on drugs that failed to receive approval by the ,food and ,drug ,administration2 and 7#b7 a list of drugs and drug prices of other manufacturers for purposes of comparison with the manufacturer's own drugs and drug prices4 7c7 ,special rule ,a drug manufacturer shall-- 7#a7 to the extent possible1 disaggregate the information required to be reported by this section by the particular drug involved2 and 7#b7 submit all information required to be reported by this section with respect to each applicable drug in a single annual report4 7d7 ,submission of reports 7#a7 ,in general 7,a7 ,submission by drug manufacturers ,drug manufacturers shall submit the annual reports required under this section to the ,secretary in a usable format1 as the ,secretary may require4 7,b7 ,collation by the ,secretary ,the ,secretary shall collate the reports received as described in subparagraph 7,a7 and submit such collated reports to ,congress1 together with an analysis of the reports by the ,secretary that includes-- 7i7 a summary of data from the reports2 7ii7 consideration of factors such as trends on research and development costs1 ,federal benefits1 and manufacturer patient assistance programs2 and 7iii7 the relationship between the factors described in clause 7ii7 and prescription drug prices4 7,c7 ,public availability ,the ,secretary shall make the reports submitted by manufacturers as described in subparagraph 7,a7 and the collated reports together with the analysis of the ,secretary described in subparagraph 7,b7 publicly available1 including by posting such reports to the internet website of the ,department of ,health and ,human ,services1 in a searchable format4 7#b7 ,initial report 7,a7 ,in general ,a drug manufacturer shall submit an initial report pursuant to this section not later than one year after the date of enactment of this subparagraph 7except as provided in subparagraph 7,b774 7,b7 ,reporting period ,notwithstanding the requirement in subsection 7a7 that each report under such subsection be for the previous calendar year1 the initial report of a drug manufacturer under subsection 7a7 shall include1 for each drug marketed by the manufacturer1 the information described in paragraphs 7#a7 through 7#f7 of subsection 7a7 for the calendar year period beginning with the later of-- 7i7 the calendar year in which the drug was approved under section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act1 was licensed under section #cea of this ,act1 or received an exemption under section #eje7;i7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act or section #cea7;a77#c7 of this ,act2 and 7ii7 the calendar year in which the manufacturer acquired the drug so approved1 licensed1 or exempted4 7,c7 ,small businesses ,in the case of a drug manufacturer that has fewer than #ejj employees1 the initial report required by in subparagraph 7,a7 shall be submitted by a date determined by the ,secretary1 which shall be-- 7i7 not earlier than the deadline described in subparagraph 7,a72 and 7ii7 not later than the date that is #c years after the date of enactment of this clause4 7e7 ,audit by third party ,the ,secretary shall select a percentage 7to be determined by the ,secretary7 of the reports submitted under subsection 7a7 for a fiscal year to be audited by an accredited third-party auditor 7to be selected by the ,secretary74 7f7 ,penalty for noncompliance ,the ,secretary shall report to the ,office of the ,inspector ,general any manufacturer's failure to submit a complete report as required under this section4 ,any manufacturer that fails to submit a complete report required under this section shall be subject to a civil penalty of up to #bjj1jjj for each day on which the violation continues4 ,the ,secretary shall collect the civil penalties under this subsection and1 without further appropriation1 shall use such funds to support research of the ,national ,institutes of ,health4 7g7 ,definition ,in this section1 the term drug manufacturer means the manufacturer of an approved drug 7including a drug approved under subsection 7c7 or 7j7 of section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act and a biological product licensed under subsection 7a7 or 7k7 of section #cea of this ,act74 4